Grant: Operating Grant
McMaster University
$265,076.00
Pathogen Inactivation of the Blood Supply: Exploring stakeholder perceptions of a new technology
FY 2008-09
Summary
In Canada the safety of the blood supply has increased as transmissible organisms have been identified, and screening
tests developed to detect viral threats. This reactive approach has reduced the risk of transfusion-related infectious disease,
but does not deal with the risk from unknown organisms. In the past the time-lag between the identification of new viruses
and the development of effective screening tests has resulted in the spread of serious infections through transfusions (e.g.
hepatitis C and HIV).Thus, research is ongoing to develop proactive ways of destroying organisms which may cause
infection. This new technology, Pathogen Inactivation (PI), exposes blood to chemicals, lights, or washes, killing both known
and unknown viruses, bacteria and parasites in blood. Though some of these technologies are now available for use they
may carry risks. Chemicals used in some of the techniques are potentially carcinogenic. Although they are removed from
the blood product after treatment, the long term effects of exposing individuals to possible trace elements from these
chemicals is not yet known. No research has sought to understand what health professionals or the public think about PI. It
is important to gather this information before decisions can be made about moving forward with this approach.
This study will explore professional and public perceptions regarding the use of PI. We will conduct focus groups and interviews with individuals who have and have not received blood transfusions, physicians who use blood products hospital Transfusion Medicine personnel, and representatives from the blood suppliers and
the government regulator. The results will be used to develop a survey for distribution to a large portion of the Canadian
public. All results will be presented to professionals and the public for feedback, and final reports will help guide policy
development regarding PI of the blood supply in Canada
Department
Program
Operating Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
180722
Name
Heddle Nancy M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Health systems / services
Prcname2
Health Services Evaluation & Interventions Research - A
Projecttitle
Pathogen Inactivation of the Blood Supply: Exploring stakeholder perceptions of a new technology
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$265,076
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Blood; New Technology; Pathogen Inactivation; Policy; Risk
Abstract
In Canada the safety of the blood supply has increased as transmissible organisms have been identified, and screening
tests developed to detect viral threats. This reactive approach has reduced the risk of transfusion-related infectious disease,
but does not deal with the risk from unknown organisms. In the past the time-lag between the identification of new viruses
and the development of effective screening tests has resulted in the spread of serious infections through transfusions (e.g.
hepatitis C and HIV).Thus, research is ongoing to develop proactive ways of destroying organisms which may cause
infection. This new technology, Pathogen Inactivation (PI), exposes blood to chemicals, lights, or washes, killing both known
and unknown viruses, bacteria and parasites in blood. Though some of these technologies are now available for use they
may carry risks. Chemicals used in some of the techniques are potentially carcinogenic. Although they are removed from
the blood product after treatment, the long term effects of exposing individuals to possible trace elements from these
chemicals is not yet known. No research has sought to understand what health professionals or the public think about PI. It
is important to gather this information before decisions can be made about moving forward with this approach.
This study will explore professional and public perceptions regarding the use of PI. We will conduct focus groups and interviews with individuals who have and have not received blood transfusions, physicians who use blood products hospital Transfusion Medicine personnel, and representatives from the blood suppliers and
the government regulator. The results will be used to develop a survey for distribution to a large portion of the Canadian
public. All results will be presented to professionals and the public for feedback, and final reports will help guide policy
development regarding PI of the blood supply in Canada
Competitiondate
200903
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Heddle, Nancy M; Eyles, John D
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $265,076~ $0~